Patients with difficult-to-treat or suboptimally controlled asthma consume a disproportionate share of asthma health care resources. Treatment strategies that minimize exacerbations may decrease the need for unscheduled medical services, reduce emergency department visits, and minimize asthma-related hospitalizations. Clinical trial evidence indicates the immunoglobulin-E blocker omalizumab reduces the frequency of asthma exacerbations, minimizes symptoms, and improves lung function in patients with moderate-to-severe asthma that is inadequately controlled by inhaled corticosteroid therapy. Treatment with omalizumab of patients with suboptimally controlled asthma may reduce the clinical and economic burden of asthma.
|Original language||English (US)|
|Number of pages||6|
|Journal||Managed care interface|
|State||Published - Jan 2004|
ASJC Scopus subject areas
- Health Policy